That includes the recent decision to reject NHS use of AZ and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for HER2-low ...

There was a standoff between USAID and Elon Musk's Department of Government Efficiency (DOGE) over access to restricted areas ...

Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after getting confirmation it will be covered by the NHS in all four nations.

Precision medicine, also known as personalised medicine, is transforming healthcare by providing tailored treatments to patients suffering from life-threatening conditions. We are all unique, and ...

A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today with the promise of delivering a "transformation" in the study of diseases and ...

Companies have been trying to expedite and optimise drug trials for ages. They’re the most expensive part of the drug development process and are often subject to setbacks in the process of ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...

Transitioning from my role as a pharmacist to becoming a project manager in healthcare technology was not just a professional milestone, but a deeply transformative journey. As a pharmacist, I saw ...